Celltrion Leads Asian Markets in Autoimmune and Cancer Drug Share; Expands Subsequent Product Launches

Celltrion has solidified its position as a market leader across key Asian countries with its flagship autoimmune disease treatment Remsima and its anticancer drugs. The company's strategic direct sales operations in Malaysia, Singapore, and Thailand are tailored to each nation's specific healthcare systems and tender processes, contributing to its sustained market dominance.

Data from IQVIA reveals Remsima captured a 93% market share in Singapore as of the first quarter of 2026, also holding leading positions in Hong Kong (84%), Thailand (78%), and Malaysia (72%). The anticancer drug Truxima mirrors this success, achieving 93% market share in Singapore and 78% in Thailand. Another oncology treatment, Herzuma, holds a 51% share in Malaysia and 42% in Thailand.

Furthermore, Celltrion's biosimilar to bevacizumab, Vegzelma, demonstrates significant growth in Malaysia. Its performance in the fourth quarter of last year was particularly notable among bevacizumab products in the local market, indicating a broadening portfolio and expanding market penetration for the company in the region.